Published in:
01-12-2017 | Breast Oncology
Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial
Authors:
Daniel Rea, BSc, MBBS, PhD, FRCP, Adele Francis, MBChB, PhD, FRCS, Matthew Wallis, MBChB, FRCR, Jeremy Thomas, FRCPath, John Bartlett, BSc, PhD, FRCPath, Sarah Bowden, PhD, BSc, David Dodwell, MD, Lesley Fallowfield, DBE, BSc, DPhil, F.Med.Sci., Claire Gaunt, BSc (Hons), Andrew Hanby, BM, FRCPath, Valerie Jenkins, DPhil, BSc, SRN, Lucy Matthews, BSc (Hons), Sarah Pinder, FRCPath, Sarah Pirrie, MSc, Malcolm Reed, MD, FRCS, Margaret Wilcox, Tracy Roberts, PhD, Cliona Kirwan, MBBS, BSc, FRCS, PhD, Cassandra Brookes, BSc (Hons), MSc, Patricia Fairbrother, Lucinda Billingham, BSc, MSc, PhD, CStat, Andrew Evans, FRCR, Jennie Young, BA (Hons)
Published in:
Annals of Surgical Oncology
|
Special Issue 3/2017
Login to get access
Excerpt
We read with interest and concern the article by Pilewskie et al.
1 The author’s study claims to match a series of patients whom they have interpreted as fulfilling the eligibility for inclusion in the Low-Risk Ductal Carcinoma in Situ (LORIS) trial from retrospective cases diagnosed with ductal carcinoma in situ (DCIS) and treated with surgery. Their stated aim was to explore the safety of an observation approach as an alternative management strategy for DCIS outside the context of a clinical trial, and they report an upgrade from DCIS to invasive cancer in 20% (58/296) of cases examined. …
